Menderes Gulden, Schwab Carlton L, Black Jonathan, Santin Alessandro D
a Department of Obstetrics, Gynecology & Reproductive Sciences , Yale University School of Medicine , New Haven , CT , USA.
Expert Rev Clin Immunol. 2016 Jun;12(6):681-95. doi: 10.1586/1744666X.2016.1147957. Epub 2016 Feb 15.
Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States. While the treatment options have improved with conventional cytotoxic chemotherapy and advanced surgical techniques, disease recurrence is common and fatal in nearly all cases. Current evidence suggests that the immune system and its ability to recognize and eliminate microscopic disease is paramount in preventing recurrence. The goal of immunotherapy is to balance the activation of the immune system against cancer while preventing the potential for tremendous toxicity elicited by immune modulation. In this paper we will review the role of immune system in disease pathogenesis and different immunotherapies available for the treatment of ovarian cancer as well as current ongoing studies and potential future directions.
卵巢癌是美国妇科恶性肿瘤致死的主要原因。尽管传统细胞毒性化疗和先进手术技术使治疗选择有所改善,但疾病复发很常见,且几乎在所有病例中都是致命的。目前的证据表明,免疫系统及其识别和消除微小病灶的能力对于预防复发至关重要。免疫疗法的目标是在激活免疫系统对抗癌症的同时,防止免疫调节引发巨大毒性的可能性。在本文中,我们将综述免疫系统在疾病发病机制中的作用、可用于治疗卵巢癌的不同免疫疗法,以及当前正在进行的研究和潜在的未来方向。